PL3255046T3 - Inhibitor kinaz zależnych od cyklin hydroksyetylosulfonian, jego forma krystaliczna oraz sposób jego otrzymywania - Google Patents
Inhibitor kinaz zależnych od cyklin hydroksyetylosulfonian, jego forma krystaliczna oraz sposób jego otrzymywaniaInfo
- Publication number
- PL3255046T3 PL3255046T3 PL16746062T PL16746062T PL3255046T3 PL 3255046 T3 PL3255046 T3 PL 3255046T3 PL 16746062 T PL16746062 T PL 16746062T PL 16746062 T PL16746062 T PL 16746062T PL 3255046 T3 PL3255046 T3 PL 3255046T3
- Authority
- PL
- Poland
- Prior art keywords
- cyclin
- preparation
- crystalline form
- protein kinase
- kinase inhibitor
- Prior art date
Links
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510056995 | 2015-02-03 | ||
| EP16746062.5A EP3255046B1 (en) | 2015-02-03 | 2016-01-12 | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor |
| PCT/CN2016/070636 WO2016124067A1 (zh) | 2015-02-03 | 2016-01-12 | 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3255046T3 true PL3255046T3 (pl) | 2020-05-18 |
Family
ID=56563428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16746062T PL3255046T3 (pl) | 2015-02-03 | 2016-01-12 | Inhibitor kinaz zależnych od cyklin hydroksyetylosulfonian, jego forma krystaliczna oraz sposób jego otrzymywania |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10030018B2 (pl) |
| EP (1) | EP3255046B1 (pl) |
| JP (1) | JP6920993B2 (pl) |
| CN (1) | CN106661025B (pl) |
| AU (1) | AU2016214897B9 (pl) |
| CA (1) | CA2974021A1 (pl) |
| CY (1) | CY1122514T1 (pl) |
| DK (1) | DK3255046T3 (pl) |
| ES (1) | ES2764139T3 (pl) |
| HR (1) | HRP20192286T1 (pl) |
| HU (1) | HUE047626T2 (pl) |
| LT (1) | LT3255046T (pl) |
| MX (1) | MX382058B (pl) |
| PL (1) | PL3255046T3 (pl) |
| PT (1) | PT3255046T (pl) |
| RS (1) | RS59782B1 (pl) |
| SI (1) | SI3255046T1 (pl) |
| SM (1) | SMT201900722T1 (pl) |
| TW (1) | TWI706951B (pl) |
| WO (1) | WO2016124067A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816437B (zh) | 2016-03-29 | 2018-08-03 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
| TWI762784B (zh) * | 2018-05-23 | 2022-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 |
| CN110790748B (zh) * | 2018-08-02 | 2022-04-19 | 江苏豪森药业集团有限公司 | 细胞周期蛋白依赖性激酶抑制剂的对甲苯磺酸盐晶型及其制备方法和用途 |
| CN110840892A (zh) * | 2018-08-21 | 2020-02-28 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 |
| BR112021014820A2 (pt) * | 2019-01-30 | 2021-09-28 | Jiangsu Hengrui Medicine Co., Ltd. | Uso da composição contendo inibidor de cdk4/6 em combinação com anastrozol na preparação de medicamento para tratar doenças tumorais |
| WO2021063332A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004017474D1 (de) * | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| KR20090052385A (ko) * | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | 2-（피리딘-2-일아미노）-피리도［2,3-ｄ］피리미딘-7-온의합성 |
| WO2014183520A1 (zh) * | 2013-05-17 | 2014-11-20 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
-
2016
- 2016-01-12 DK DK16746062.5T patent/DK3255046T3/da active
- 2016-01-12 CA CA2974021A patent/CA2974021A1/en active Pending
- 2016-01-12 ES ES16746062T patent/ES2764139T3/es active Active
- 2016-01-12 HR HRP20192286TT patent/HRP20192286T1/hr unknown
- 2016-01-12 PT PT167460625T patent/PT3255046T/pt unknown
- 2016-01-12 HU HUE16746062A patent/HUE047626T2/hu unknown
- 2016-01-12 PL PL16746062T patent/PL3255046T3/pl unknown
- 2016-01-12 LT LTEP16746062.5T patent/LT3255046T/lt unknown
- 2016-01-12 US US15/546,405 patent/US10030018B2/en active Active
- 2016-01-12 RS RS20191639A patent/RS59782B1/sr unknown
- 2016-01-12 JP JP2017536246A patent/JP6920993B2/ja not_active Expired - Fee Related
- 2016-01-12 MX MX2017009270A patent/MX382058B/es unknown
- 2016-01-12 WO PCT/CN2016/070636 patent/WO2016124067A1/zh not_active Ceased
- 2016-01-12 SI SI201630568T patent/SI3255046T1/sl unknown
- 2016-01-12 AU AU2016214897A patent/AU2016214897B9/en not_active Ceased
- 2016-01-12 SM SM20190722T patent/SMT201900722T1/it unknown
- 2016-01-12 EP EP16746062.5A patent/EP3255046B1/en active Active
- 2016-01-12 CN CN201680001816.3A patent/CN106661025B/zh active Active
- 2016-01-20 TW TW105101679A patent/TWI706951B/zh not_active IP Right Cessation
-
2018
- 2018-04-13 US US15/952,234 patent/US10160759B2/en active Active
-
2019
- 2019-12-11 CY CY20191101295T patent/CY1122514T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20192286T1 (hr) | 2020-03-20 |
| AU2016214897A1 (en) | 2017-08-10 |
| DK3255046T3 (da) | 2020-01-20 |
| TW201629060A (zh) | 2016-08-16 |
| LT3255046T (lt) | 2020-01-10 |
| PT3255046T (pt) | 2020-01-06 |
| WO2016124067A1 (zh) | 2016-08-11 |
| EP3255046A4 (en) | 2018-10-10 |
| JP6920993B2 (ja) | 2021-08-18 |
| MX2017009270A (es) | 2017-10-11 |
| ES2764139T3 (es) | 2020-06-02 |
| AU2016214897B2 (en) | 2020-05-21 |
| CN106661025B (zh) | 2019-08-16 |
| US10160759B2 (en) | 2018-12-25 |
| AU2016214897B9 (en) | 2020-06-04 |
| HUE047626T2 (hu) | 2020-05-28 |
| CN106661025A (zh) | 2017-05-10 |
| JP2018503634A (ja) | 2018-02-08 |
| TWI706951B (zh) | 2020-10-11 |
| US20180009804A1 (en) | 2018-01-11 |
| MX382058B (es) | 2025-03-13 |
| US10030018B2 (en) | 2018-07-24 |
| SMT201900722T1 (it) | 2020-03-13 |
| RS59782B1 (sr) | 2020-02-28 |
| US20180230147A1 (en) | 2018-08-16 |
| SI3255046T1 (sl) | 2020-02-28 |
| EP3255046A1 (en) | 2017-12-13 |
| CY1122514T1 (el) | 2021-01-27 |
| CA2974021A1 (en) | 2016-08-11 |
| EP3255046B1 (en) | 2019-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| SMT201900722T1 (it) | Idrossietil solfonato di inibitore di proteina chi-nai ciclina-dipendente, sua forma cristallina e metodo di preparazione per lo stesso | |
| PL3372607T3 (pl) | Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania | |
| ZA201700786B (en) | Protein kinase c inhibitors and methods of their use | |
| EP3216790A4 (en) | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof | |
| EP3250192A4 (en) | Compositions and methods of using tyrosine kinase inhibitors | |
| EP3265093A4 (en) | Tricyclic kinase inhibitors of melk and methods of use | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| PL3447051T3 (pl) | Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej | |
| GB201612205D0 (en) | Superhard constructions & methods of making same | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| ZA201802141B (en) | Egfr kinase inhibitor and preparation method and use thereof | |
| EP3284746A4 (en) | Preparation and use of kinase inhibitor | |
| EP3193874A4 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
| SI3327012T1 (sl) | Kristalinične oblike bilastina in postopki za pripravo le-teh | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| HK40029221A (en) | Kinase inhibitors and methods for making and using | |
| HK1261294A1 (en) | Process for the preparation of kinase inhibitors and intermediates thereof |